Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

May 2015

Two New Medical Policies Now Available 

Harvard Pilgrim has developed two new medical policies —Surgical Treatment of Idiopathic Scoliosis and Stem Cell Transplantation — to provide guidance on when Harvard Pilgrim considers these treatments medically necessary.  Harvard Pilgrim does not require prior authorization for either of these therapies.

Surgical Treatment of Idiopathic Scoliosis

A number of different surgeries are used to treat idiopathic scoliosis (a curvature of the spine greater than 10 degrees whose cause is unknown) when patients exhibit progressive deformity or when bracing or other treatments have failed or are contraindicated. As the Surgical Treatment of Idiopathic Scoliosis Medical Policy details, Harvard Pilgrim considers surgical treatment necessary under the following conditions.

For adults, when all of the following apply to the patient:

  • Has a coronal standing Cobb angle of greater than or equal to 45 degrees
  • Tried NSAIDS or acetaminophen for at least 3 weeks, unless medically contraindicated
  • Engaged in home exercise or physical therapy for 12 weeks or more
  • Modified activity for 12 weeks or more
  • Continued symptoms or findings after treatment

For infants, children, and adolescents, when all of the following apply:

  • The patient has a coronal standing Cobb angle of greater than or equal to 45 degrees.
  • Follow up X-rays show a curve progression in a skeletally immature patient.

For patients of all ages, Harvard Pilgrim considers vertebral body stapling experimental and unproven for the treatment of scoliosis because its long-term effectiveness has not been established. For complete information, please refer to the Surgical Treatment of Idiopathic Scoliosis Medical Policy posted on Harvard Pilgrim’s provider website.

Stem Cell Transplantation

Hematopoietic stem cell transplantation is now commonly used to treat patients with hematologic malignancies (tumors that affect the blood, bone marrow, lymph, and lymphatic system), as well as clinical and acquired bone marrow failure, including radiation injury.

Harvard Pilgrim covers non-experimental stem cell transplantation and related procedures that are reasonable and medically necessary for individuals with specific conditions. Covered conditions include:

  • Autologous stem cell transplantation: Hodgkin lymphoma, multiple myeloma, non-Hodgkin lymphoma, primary (al) amyloidosis , testicular germ cell tumor, acute promyelocytic leukemia (in second remission) (aml m3), and pediatric cancers.
  • Allogeneic stem cell transplantation: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), aplastic anemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), Hodgkin lymphoma, myelodysplastic syndrome , non-Hodgkin lymphoma. Also covered are advanced myeloproliferative neoplasms/disorders (MPD/MPN) including primary myelofibrosis, secondary myelofibrosis (spent phase of P. Vera, ET), and chronic myelomonocytic leukemia (CMML).

For complete information, please see the Stem Cell Transplantation Medical Policy posted on Harvard Pilgrim’s provider website.

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


New Updates Coming to HPHConnect

Harvard Pilgrim’s Preparations for ICD-10 Transition


Improvement in Coordination of Benefits Process

Coverage for Artificial Cervical Disc Replacement with Prior Authorization

Two New Medical Policies Now Available

Complex Case Management Services

Disease Management Programs that Reinforce Physician Treatment Plans

Specialty Pharmacy Program Updates

Reminder of Member Cost Sharing Waiver Policies

Collaboration among PCPs and Behavioral Health Providers


2015 Update of the Home Care Seasonal Flu Vaccine Fee Schedule

Reminder: Ensure That Claims Contain Valid Codes


Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator